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Abstract
Introduction Pulmonary vein (PV) reconnection is fre-
quently the cause of recurrence of atrial fibrillation (AF)
after ablation. The second-generation gold multi-electrode
ablation (Gold-MEA) catheter has a new design possibly
resulting in improved lesion formation compared with its
predecessor. We aimed to determine the association be-
tween effective radiofrequency applications with the Gold-
MEA catheter and outcome after AF ablation.
Methods 50 consecutive patients with paroxysmal AF un-
derwent Gold-MEA (PVAC GOLDTM, Medtronic Inc.) ab-
lation. The Gold-MEA catheter was navigated to the PV os-
tium by fluoroscopy. Duty-cycled radiofrequency ablations
were performed at all PV ostia. Lesions were considered
transmural when electrode temperature was >50 °C and
power >3 W for >30 seconds. After the ablation procedure,
patients visited the outpatient clinic at 3-month intervals
including 24-hour Holter ECGs.
Results Mean age was 56 years. All PVs were acutely
isolated with the Gold-MEA catheter. Procedure time was
111 ± 22 minutes, ablation time was 24 ± 6.7 minutes and
fluoroscopy time was 20 ± 8.1 minutes. No procedure-re-
lated complications were observed. One year after ablation,
60 % of patients were still free of arrhythmia recurrences
after a single PV isolation attempt. The number of trans-
mural lesions was associated with arrhythmia-free survival:
25.0 % in <72 transmural lesions, 64.3 % in 72–108 trans-
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mural lesions and 71.4 % in >108 transmural lesions (p =
0.029).
Conclusion PV isolation can be performed successfully
with the Gold-MEA catheter, with a favourable safety pro-
file. Transmurality of lesions was associated with ablation
success and may improve AF ablation success.
Keywords Atrial fibrillation · Ablation · Multi-electrode
ablation · Effective energy · PVAC Gold
Introduction
Pulmonary vein isolation (PVI) has become an important
treatment modality for symptomatic atrial fibrillation (AF)
[1, 2]. The dominant triggers for paroxysmal AF come from
the pulmonary veins (PVs). During PVI, a circumferential
lesion set is created at the base of the PVs so that these PVs
are electrically isolated from the left atrium [1, 2]. Sev-
eral techniques are used to perform the ablation, including
point-by-point radiofrequency (RF) catheter ablation, [3, 4]
cryoballoon ablation, [5] laser balloon ablation [5–8] and
multi-electrode ablation (MEA) [3, 9, 10]. The last-men-
tioned is no longer in use due to its association with asymp-
tomatic cerebral embolism, [11–14] but the newly designed
gold multi-electrode ablation (Gold-MEA) catheter, build-
ing on its predecessor, combines several characteristics that
may improve lesion formation and reduce complications.
Although PVI has proven to be an effective treatment for
AF, some patients develop recurrences [3, 15]. Electrical
reconnection of the PVs is considered the most important
mechanism for AF recurrence [2]. In contrast to other ab-
lation techniques, there is no surrogate marker for transmu-
rality of lesions for the Gold-MEA catheter. We aimed to
report the ablation characteristics of 50 patients, determine
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transmurality of lesions with the Gold-MEA catheter and
describe its association with ablation outcome.
Methods
Patient population
Fifty consecutive patients with symptomatic paroxysmal
AF who were accepted for primo PVI in our centre were
included in this study. Data were collected in a prospec-
tive hospital database. All patients consented to their data
being registered and used for publication, as did the Board
of Hospital Administrators.
Preablation protocol
All patients underwent a CT scan, to assess left atrial and
pulmonary vein (PV) anatomy. Patients with common PV
ostia, both left and right, were excluded from this analy-
sis, as well as patients with accessory PVs. Patients were
admitted 24 hours before the ablation procedure. During
hospitalisation, the cardiac rhythm was continuously mon-
itored in all patients. Transthoracic echocardiography was
performed routinely 1 day before ablation to determine right
and left ventricular function, valvular abnormalities, and
left and right atrial dimensions. Transoesophageal echocar-
diography was performed directly pre-ablation to assess
the interatrial septum and to rule out intracardiac throm-
bus and/or severe aortic plaques. Routine blood tests were
performed, including electrolytes and cardiac enzymes. Pa-
tients who used oral anticoagulants were ‘bridged’ using
low-molecular-weight heparins up to 3 days prior to the
ablation procedure, in accordance with local guidelines.
Ablation protocol
All ablation procedures were performed under general
anaesthesia supervised by a cardiovascular anaesthesiol-
ogist. After placement of a 6F quadripolar catheter in
the coronary sinus via a transfemoral approach, a single
transseptal puncture was performed using a Brocken-
brough needle under fluoroscopic and pressure guidance.
Immediately after the transseptal puncture, 10,000 IU of
unfractionated heparin was administered. An 8.5F sheath
(SL-1, St. Jude Medical, Minnetonka, MN, USA) was used
for PV angiography. All sheaths were continuously flushed
with saline containing 2500 IU heparin per 500 ml saline.
An activated clotting time between 300 and 350 seconds
was targeted. Additional heparin was administered when
needed. The activated clotting time was checked during
the procedure at regular intervals of 30 minutes.
Multi-electrode catheter ablation
The multi-electrode pulmonary vein RF ablation catheter
(PVAC GoldTM, Medtronic, Minneapolis, MN, USA) is
a mapping and ablation catheter with a 25 mm diameter
circular electrode array. This catheter has a bidirectional
steering mechanism and an over-the-wire design. Com-
pared with its predecessor, the novel Gold-MEA catheter
consists of 9 gold electrodes positioned with 3.75 mm in-
ter-electrode spacing at a 20° forward tilt for optimal elec-
trode-tissue energy transfer, as displayed in Fig. 1. The
GENius generator (Medtronic, Minneapolis, MN, USA)
delivers duty-cycled bipolar and unipolar phased RF en-
ergy to all or selected electrode pairs. RF is delivered in
a temperature-controlled and power-limited fashion (60 °C,
maximum 10 W) with a typical ablation duration of 60 sec-
onds.
The Gold-MEA catheter was introduced into the left
atrium via a 10F SL-1 sheath. Using a 0.032 inch guidewire
placed in the PV, the catheter was positioned at the antrum
of each PV to record local electrical activity at the veno-
atrial junction prior to RF energy application, creating PV
templates. RF energy was applied using the RF generator
(Medtronic GENius, Minneapolis, MN, USA) with a target
temperature setting of 60 °C, RF energy setting of 2:1 ratio
between bipolar and unipolar energy, and 60-second RF ap-
plication duration. After each application, PV triggers were
assessed. Multiple applications of RF were delivered using
the available energy settings until isolation of each PV was
achieved. Furthermore, after phased RF ablations were per-
formed at all veno-atrial junctions, the Gold-MEA catheter
was used to remap all PV ostia. If the PVs appeared to
be incompletely isolated, additional RF applications were
delivered using the Gold-MEA until the PV isolation was
achieved. No adenosine testing was performed.
To aid in delivering adequate lesions, the RF generator
displays temperature and RF power in a green bar when
the temperature is >50 °C and RF power >3 W. If either
the temperature is <50 °C or the RF power is <3 W, the
colour of the bar changes to yellow. This is based on previ-
ous research in animal studies which demonstrated that the
positive predictive value of an ablation with a temperature
>50 °C and RF power >3 W for >30 seconds to predict
a transmural lesion was 99 % [16]. In the current study,
electrodes with a temperature <50 °C or RF power <3 W
were switched off during phased RF energy application.
Post-ablation management
Patients were hospitalised for at least 24 hours and moni-
tored telemetrically. Oral anticoagulants were resumed im-
mediately after the procedure, with a target INR of 2.5–3.5,
in accordance with local guidelines. Low-molecular-weight
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Fig. 1 PVAC Gold Design.
a Displays the newly designed
Gold-MEA catheter; b displays
the Platinum-MEA catheter.
Several key improvements have
been implemented: the ablation
electrodes are made of Gold
(Au) instead of Platinum (Pt);
the new catheter consists of
9 electrodes, to prevent overlap
of the 1st and 10th ablation
electrode; the inter-electrode
spacing is increased to 3.75 mm
to retain the effective arc length
and finally the electrodes are
at a 20º forward tilt. MEA
multi-electrode ablation
heparin was administered in a patient-weight dependent
dose until the INR was adequate. Complications were de-
fined according to the HRS/EHRA/ECAS expert consensus
statement on AF ablation [2]. Cerebral imaging was not
performed routinely to assess asymptomatic cerebral em-
bolism.
Follow-up
A blanking period of 3 months was defined after PVI. Pa-
tients visited the outpatient clinic at 3, 6 and 12 months
after PVI; this included a 24-hour Holter ECG. All patients
were >12 months after their first AF ablation attempt. Pa-
tients were immediately referred to the emergency room in
case of symptoms. If no arrhythmias could be detected,
patients underwent Holter ECG monitoring to exclude ar-
rhythmia recurrence. An attempt was made to discontinue
antiarrhythmic drugs in all patients 3 months after the ab-
lation.
Study endpoints
The primary endpoint of our study was arrhythmia-free
survival, defined as patients without AF/atrial flutter/atrial
tachycardia recurrence after a blanking period of 3 months.
Arrhythmia recurrence was defined as an ECG showing the
characteristics of AF/atrial flutter/atrial tachycardia, or on
a 30-second telemetry strip, in accordance with the HRS/
EHRA/ECAS expert consensus statement on AF ablation
[2]. Patients who were still using antiarrhythmic drugs
3 months after the ablation were considered arrhythmia re-
currences, in accordance with the HRS/EHRA/ECAS ex-
pert consensus statement [2].
Statistical analyses
Data are mentioned as means ± standard deviation, in-
terquartile range or percentage where appropriate. Sta-
tistical significance between variables was calculated by
the Student’s t-test (unpaired) for continuous variables and
Chi-square test for categorical variables. Effective elec-
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Fig. 2 Arrhythmia recur-
rence-free survival after ablation
with the Gold-MEA catheter.
This figure displays the AF-free
survival after ablation with the
Gold-MEA catheter. The overall
recurrence free survival is dis-
played in red. P-value between
transmural lesion groups. MEA
multi-electrode ablation
trode-tissue contact creating a transmural lesion was defined
as any ablation with a temperature >50 °C and RF power
>3 W for over 30 seconds [16]. Patients were categorised
into <72 transmural lesions, 72–108 transmural lesions and
>108 transmural lesions. Kaplan-Meyer analysis with a log-
rank test was used to compare transmural lesion groups. To
assess the learning curve, the first 25 patients were cate-
gorised to the first cohort and the following 25 patients to
the second cohort. The follow-up duration between cohorts
was compared with a Mann-Whitney U test. A p-value
of 0.05 was regarded significant. Statistical analysis was
performed using IBM Statistics version 22.0 (IBM SPSS
Statistics for Windows, 2011: Armonk, New York, USA).
Results
Fifty consecutive patients with paroxysmal AF were in-
cluded, mean age was 57.1 ± 11.7 years. No left atrial
thrombi were found during the preoperative transoe-
sophageal echocardiogram. Of note, no patients had com-
mon left or right PV ostia and no patients had accessory
PVs on the pre-ablation CT scan. Baseline characteristics
are displayed in Table 1.
Procedural characteristics
In all 200 PVs, acute PVI was achieved. The mean pro-
cedure duration was 111 ± 22 minutes, with a range of
60 to 150 minutes. The mean ablation time was 23.5 ±
6.7 minutes, with a range of 12 to 42 minutes. The mean
fluoroscopy time was 20.1 ± 8.1 minutes, with a range of
9 to 45 minutes. None of the patients developed complica-
tions related to the procedure and, in particular, no patients
developed symptomatic thromboembolic events.
Ablation outcome
All patients were >1 year after their initial ablation proce-
dure when the present analysis was conducted. One year
after ablation, 20 (40 %) of patients developed an arrhyth-
mia recurrence, whereas 30 (60 %) remained free of ar-
rhythmia recurrences and off antiarrhythmic drugs after
a single PVI attempt. The arrhythmia-free survival is dis-
played in Fig. 2.
Transmural lesions
Transmural lesions, defined as any ablation with a temper-
ature >50 °C and RF power >3 W for over 30 seconds,
[16] was achieved in 44.6 % (range 23–62 %) of the to-
tal number of lesions delivered. Patients were categorised
into: <72 transmural lesions (8 patients); 72–108 trans-
mural lesions (28 patients) and >108 transmural lesions
(14 patients). Arrhythmia-free survival after one year was
significantly associated with the number of transmural le-
sions, 25 % in patients with <72 transmural lesions, 64.3 %
in patients with 72–108 transmural lesions and 71.4 % in
patients with >108 transmural lesions (p = 0.029), as dis-
played in Fig. 2. Of note, none of the patient characteristics
were associated with the number of transmural lesions.
Learning curve
The first 25 patients were compared with the following
25 patients in terms of procedural characteristics. As men-
tioned, acute PVI was achieved in all PVs. Between the
cohorts, procedure time (106 ± 25 vs. 116 ± 18 minutes,
p = 0.11), ablation time (24 ± 7.4 vs. 23 ± 6.0 minutes,
p = 0.94) and fluoroscopy time (20 ± 9.5 vs. 20 ± 6.4
minutes, p = 0.87) were comparable. The number of trans-
mural lesions was comparable in the latter cohort (91 vs.
101, p = 0.32). The differences in procedural characteristics
are displayed in Table 2 and Fig. 3. In terms of ablation
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Fig 3 Procedure, ablation and
fluoroscopy time. This figure
displays the procedure time,
ablation time and fluoroscopy
time. Note that there appears to
be no difference in any of these
variables between the first and
the second cohort, thus there
appears to be no learning curve
with the Gold-MEA catheter
for operators who are experi-
enced with the Platinum-MEA
catheter. MEA multi-electrode
ablation
outcome, there was no difference between the two cohorts:
of the first 25 patients, 14 (46.7 %) were still arrhythmia
free whereas 16 (53.3 %) patients from the second group of
25 patients were still arrhythmia free (p = 0.55). Further-
more, there were no significant differences between opera-
tors in number of applied transmural lesions (p = 0.47) as
well as arrhythmia recurrences (p = 0.15).
Discussion
The present study reports on the association between trans-
murality of lesions and AF ablation outcome in Gold-MEA
catheter ablation. In conclusion, ablation outcome is poor in
case of <72 transmural lesions, but is comparable with other
ablation techniques for >108 transmural lesions. Gold-
MEA catheter ablation is characterised by a relatively short
procedure time, and safety outcome seems to be favourable,
although this was a small study.
Catheter design
The newly designed Gold-MEA catheter builds on its pre-
decessor, but several key improvements have been imple-
mented. First, the new catheter consists of 9 electrodes, to
prevent overlap of the 1st and 10th ablation electrode. Sec-
ond, the ablation electrodes are made of gold instead of plat-
inum. In an animal study with the new Gold-MEA catheter,
gold electrodes produced more consistent power delivery
than platinum [17] without an increase in microemboli pro-
duction, potentially due to better passive convective cooling
of the electrodes [18]. Last, the catheter system now boasts
a 20 forward tilt to improve catheter-wall contact, which
improves contact by 56 % according to unpublished data
by Medtronic [19].
Procedure duration
In the present study, we observed that the new Gold-MEA
catheter achieved acute PVI in all PVs, with a relatively
short procedure time which will result in a more cost-ef-
fective approach, since more procedures can be performed
in the same amount of time compared with, for example,
conventional RF catheter ablation [3, 20] or laser balloon
ablation, [6, 21] which are characterised by procedures last-
ing 2.5–3.5 hours [22].
Complications
We did not observe any complications with the new Gold-
MEA catheter, although this study consists of a limited
patient population size. In a previous study performed in
our centre, complications after ablation with the Platinum-
MEA catheter were only 1.8 %, [3] significantly less than
conventional point by point RF catheter ablation. How-
ever, as mentioned previously, the Platinum-MEA catheter
is no longer in use due to its association with asymptomatic
cerebral embolisms. Thromboembolisms were related to
overlap between the 1st and 10th electrode in the Platinum-
MEA catheter system [23]. This resulted in local overheat-
ing of blood and PV tissue, resulting in thromboembolisms
[14]. The new Gold-MEA catheter has been re-designed
to prevent this local overheating, thereby reducing throm-
boembolic complications. Furthermore, the Precision Gold
Trial [24] will allow assessment of the incidence of asymp-
tomatic cerebral emboli in patients treated with the Gold-
MEA catheter. The present study was not aimed at assess-
ing the association between Gold-MEA catheter ablation
and asymptomatic cerebral emboli.
Ablation success
The present study shows that the overall ablation success
after a limited follow-up period seemed to be lower com-
pared with other techniques [3, 6, 20, 21]. However, our
reported success rate is comparable with the first-genera-
tion MEA catheter [25, 26]. Moreover, ablation outcome
was clearly associated with the number of transmural le-
sions. To date, no techniques are available to assess actual
lesion depth, and therefore true transmurality cannot be de-
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Table 1 Baseline characteristics
Patient characteristics Total (n = 50)
Gender female (%) 15 (30 %)
Age (years) 57.1 (±11.7)
BMI (kg/m2) 28.3 (±4.2)
Paroxysmal AF 50 (100 %)
AF duration (years) 5.1 (±7.4)
CHADS2-VA2Sc (range) 1.3 (0–5)
Congestive heart failure 5 (10 %)
LA ventral-dorsal dimension (mm) 41.1 (±3.9)
LVEF (%) 58.8 (±3.2)
History of hypertension 16 (32 %)
History of diabetes mellitus 2 (4 %)
History of TIA/CVA 7 (14 %)
Data are presented as percentages or means ± their SD or ranges
where appropriate. BMI body mass index, AF atrial fibrillation, LA left
atrium, LVEF left ventricular ejection fraction, TIA transient ischaemic
attack, CVA cerebrovascular accident





hort (n = 25)
P





Procedure time (min) 106 ± 25 116 ± 18 0.11
Ablation time (min) 24 ± 7.4 23 ± 6.0 0.94
Fluoroscopy time
(min)
20 ± 9.5 20 ± 6.4 0.87
Complications (n) 0 (0 %) 0 (0 %) >0.99
Transmural lesions (n) 91 ± 28 101 ± 24 0.32
Data are presented as percentage or means ± their SD where
appropriate
termined. Other AF ablation techniques use surrogates to
ascertain if a lesion is transmural. Contact force sensing
for conventional RF ablation with a mapping catheter was
recently introduced, allowing operators to assess the con-
tact force and force vector [27, 28]. Lesions with a force-
time integral >400 gs were significantly associated with
more durable PVI lesions and improved ablation outcome
[5, 29]. The cryoballoon allows assessment of freezing
and thawing temperature, which is indicative of the tissue
temperature and thus lesion delivery [30, 31]. Laser bal-
loon ablation allows operators to visually perform lesions
that overlap, to ensure transmurality and circumferentiality.
Based on experimental data, effective contact is considered
a useful marker of transmural lesions for the Gold-MEA
catheter. A previous animal study already demonstrated
a high positive predictive value of 99 % for effective con-
tact in achieving histologically confirmed acute and chronic
transmural lesions [16]. In the present study, we found
an association between the number of transmural lesions
based on effective contact and ablation outcome. Less than
72 transmural ablations were associated with a significantly
poor ablation outcome. Implementation of effective contact
into the Gold-MEA catheter ablation may improve ablation
outcome. However, this study was not designed to deter-
mine the optimal number of transmural lesions to achieve
durable PV isolation.
The operators who performed Gold-MEA were experi-
enced with the Platinum-MEA catheter system. No differ-
ences between operators were found regarding the number
of transmural lesions and arrhythmia recurrences.
However, although lesion quality displayed a significant
association with ablation outcome, this was predominantly
caused by patients with <72 transmural lesions. The 42 pa-
tients with >72 ablation lesions displayed a comparable
ablation outcome, even though there was still a substantial
variation in the number of transmural lesions and proportion
of patients suffering from arrhythmia recurrences. These
observations suggest that there are other factors at play that
have an impact on ablation success, on top of lesion trans-
murality. Although the present study was not designed to
investigate other factors that impact Gold-MEA ablation re-
sults, geometrical variation between patients may be one of
these factors. Previous research by our group demonstrated
that PV orientation was associated with ablation outcome
after multi-electrode ablation [32] and laser balloon abla-
tion, [33] but not after contact force sensing catheter abla-
tion [34]. Future research is necessary to determine if PV
orientation may also impact ablation outcome after Gold-
MEA ablation.
Limitations
The present study consists of a limited patient sample size,
and therefore claims on safety and PVI success may be
overestimated. Future research is warranted including more
patients with a more extended follow-up period. Single pro-
cedure ablation success is reported, whereas most previous
studies reported success after multiple PVI attempts. No
adenosine testing was performed to assess for dormant con-
duction of PVs, which could potentially result in a higher
success rate.
Conclusion
AF ablation can be performed successfully with the Gold-
MEA catheter, with a favourable safety profile. A higher
number of effective lesions, as a surrogate marker for trans-
murality of lesions, was associated with freedom of AF
during follow-up.
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